8-K: Acrivon Therapeutics Reports Positive Phase 2 Trial Data and Secures $130 Million in Private Placement

Acrivon Therapeutics announced positive results from its Phase 2 trial of ACR-368, progress with ACR-2316, and a successful $130 million private placement.

Summary

• Acrivon Therapeutics reported its second quarter 2024 financial results and provided business updates.
• The company's lead asset, ACR-368, showed a 50% overall response rate in patients with gynecological cancers who were prospectively predicted to be sensitive to the treatment.
• A 60% overall response rate was observed in endometrial cancer patients, a new tumor type identified by the AP3 platform.
• The AP3-based ACR-368 OncoSignature assay demonstrated the ability to predict which patients would respond to ACR-368 monotherapy.
• In patients who were not predicted to respond, initial clinical activity was observed when ACR-368 was combined with ultra-low dose gemcitabine.
• The company is on track to initiate a Phase 1 clinical study with ACR-2316, a WEE1/PKMYT1 inhibitor, in the fourth quarter of 2024.
• Acrivon successfully completed a $130 million private placement financing.
• The company plans to present updated ACR-368 clinical data at the ESMO conference in September 2024.
• Acrivon's net loss for the quarter ended June 30, 2024, was $18.8 million, compared to a net loss of $13.9 million for the same period in 2023.
• Research and development expenses were $15.0 million for the quarter, compared to $10.5 million in the same period of 2023.
• As of June 30, 2024, the company had $220.4 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2026.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, a successful capital raise, and a clear path forward, indicating strong positive sentiment.

Positives

• The ACR-368 trial demonstrated a strong 50% overall response rate in a specific patient population.
• The AP3 platform successfully identified a new tumor type, endometrial cancer, that is sensitive to ACR-368.
• The OncoSignature assay accurately predicted patient response to ACR-368.
• The combination of ACR-368 with ultra-low dose gemcitabine showed promise in patients not predicted to respond to ACR-368 alone.
• The company is progressing its pipeline with the planned initiation of the ACR-2316 Phase 1 trial.
• The $130 million private placement provides significant financial runway.
• The company has a strong cash position of $220.4 million.

Negatives

• The company reported a net loss of $18.8 million for the quarter ended June 30, 2024, which is higher than the $13.9 million loss for the same period in 2023.
• Research and development expenses increased to $15.0 million for the quarter, up from $10.5 million in the same period of 2023.
• General and administrative expenses also increased to $6.4 million for the quarter, compared to $5.0 million in the same period of 2023.

Risks

• The company is still in the clinical stage and faces the inherent risks of drug development.
• The OncoSignature test has not yet obtained regulatory approval.
• The company's financial losses are increasing, and it is reliant on its cash reserves.
• The company's future success depends on the successful development and commercialization of its drug candidates.

Future Outlook

The company expects its current cash reserves to fund operations into the second half of 2026 and plans to provide pipeline and platform updates in the second half of 2024, including updated ACR-368 clinical data at the ESMO conference and the initiation of a Phase 1 clinical study of ACR-2316 in 4Q 2024.

Management Comments

• We continue to make significant progress on our mission to deliver on the unique and actionable capabilities of our AP3 platform by rapidly advancing a pipeline of differentiated therapies that address high unmet need cancers, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Industry Context

Acrivon's focus on precision medicine and the use of its AP3 platform aligns with the broader industry trend towards personalized cancer treatments. The company's approach of using proteomics to predict patient response is a novel approach in the field.

Comparison to Industry Standards

• The 50% overall response rate for ACR-368 in OncoSignature-positive patients is promising compared to standard treatments for platinum-resistant ovarian and endometrial cancers, where response rates are often lower.
• Companies like Clovis Oncology (now acquired by Pharma) with Rubraca (rucaparib) and GSK with Zejula (niraparib) have achieved response rates in the 20-30% range in similar patient populations, making Acrivon's results potentially competitive.
• The use of a predictive biomarker like the OncoSignature assay is a key differentiator for Acrivon, as it aims to improve patient selection and treatment outcomes, which is a growing trend in oncology drug development.
• The development of ACR-2316, a dual WEE1/PKMYT1 inhibitor, is also notable as it addresses limitations of single-target inhibitors, which is a common challenge in the field.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and successful financing favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with advanced cancers may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will present updated ACR-368 clinical data at the ESMO conference in September 2024.
• The company plans to initiate a Phase 1 clinical study of ACR-2316 in 4Q 2024.
• The company will advance a new potential first-in-class drug discovery program towards development candidate nomination in 2025.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, AP3 platform, OncoSignature, Precision Medicine, Clinical Trial, Cancer, WEE1/PKMYT1 inhibitor, Private Placement, ESMO